Company intelligence / Profile preview
Topmunnity Therapeutics
Hong Kong, Hong Kong SAR, Chinatopmunnity.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The TT-01 ADC is preclinical and designed to relieve T cell inactivation and internalize into tumor cells to induce killing. CAR-108 CAR-T cell therapy can kill 80% of tumor cells in vitro and achieved total tumor remission in vivo animal studies
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateCAR-T cell therapyBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Topmunnity Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Topmunnity Therapeutics.